Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteriophage K
- Development stage
- Preclinical
- Lead developer
- Baylor College of Medicine
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intraarticular, Intravenous, Topical
01
Overview
Bacteriophage K (also known as phage K) is a well-characterized, strictly lytic polyvalent bacteriophage belonging to the *Myoviridae* family and *Twortvirinae* subfamily. It exhibits a broad host range and is highly active against *Staphylococcus aureus*, including methicillin-resistant *S. aureus* (MRSA), vancomycin-intermediate *S. aureus* (VISA), and other multi-drug resistant (MDR) clinical isolates. Phage K infects host bacteria by binding to cell wall components (such as wall teichoic acids), injecting its double-stranded DNA genome, replicating intracellularly, and ultimately lysing the host cell via phage-encoded endolysins (e.g., LysK). It has been investigated as an alternative or adjunctive therapeutic agent for *S. aureus* infections, including bacteremia, osteoarticular infections, and bovine mastitis. Clinical-grade preparations of phage K have been manufactured and administered to patients under FDA emergency Investigational New Drug (IND) compassionate-use protocols.
- Other names
- Staphylococcal phage KStaphylococcus aureus bacteriophage KTwortvirus Kphage K
Beyond the preview
Go deeper on bacteriophage K.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteriophage K.